Eagle Bay Advisors’s TG Therapeutics TGTX Stock Holding History

Eagle Bay Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,002	Closed	-$8.38K	–	868
2023 Q3	$8.38K	Buy	+1,002	New	+$14K	﹤0.01%	623

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Eagle Bay Advisors's TGTX Position: Q4 2023 in Review

Eagle Bay Advisors sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 1,002 shares — an estimated $8.38K sold.

Eagle Bay Advisors first reported a position in TGTX in Q3 2023 and held it in 1 quarter. The position peaked at $8.38K in Q3 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

Eagle Bay Advisors reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
Eagle Bay Advisors sold 1,002 TG Therapeutics shares in Q4 2023, an estimated $8.38K.
Eagle Bay Advisors first reported a position in TG Therapeutics in Q3 2023 and held it in 1 quarter.
Eagle Bay Advisors's TG Therapeutics position peaked at $8.38K in Q3 2023.
235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Eagle Bay Advisors's 13F filing for Q4 2023, filed 8 Feb 2024.